Abstract
Two antiviral treatments have been approved for hepatitis B virus (HBV) infection by the US Food and Drug Administration (FDA) for use in children: interferon (IFN)-α, 6 MU/m2 three times a week subcutaneously for 6 months, and lamivudine, 3 mg/kg/d orally for 12 months. Twenty-six percent to 58% of children treated with IFN become HBV DNA negative, and up to 38% become negative to hepatitis B e antigen (HBeAg). Lamivudine, a nucleoside analogue that blocks viral replication by inhibition of the HBV polymerase, has been associated with comparable rates of seroconversion of HBeAg to anti-HBe. Loss of surface antigen occurs in less than 5% of patients treated with lamivudine, compared with 3% to 33% in those treated with IFN-α. Fifty percent to 65% of children treated with lamivudine clear HBV DNA after 12 months of therapy, but relapse rates have not been clarified. Patients treated with lamivudine develop drug-resistant (YMDD) mutants in the HBV polymerase at the rate of 16% to 32% per year. No treatments for children with hepatitis C virus (HCV) have been approved by the FDA. However, published reports describe treatment with IFN monotherapy and combination therapy with IFN and ribavirin. Trials of PEG-IFN alone or in combination with ribavirin are in progress. Given the lack of data regarding treatment of HCV in children, it is generally agreed among pediatric hepatologists that the optimal treatment is within the context of randomized, controlled trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hsu HM, Lu CF, Lee SC, et al.: Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999, 179:367–370.
Viviani S, Jack A, Hall AJ, et al.: Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946–2950.
Mahoney FJ, Woodruff BA, Erben JJ, et al.: Effect of hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J Infect Dis 1993, 167:203–207.
Chang MH, Chen CJ, Lai et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855–1859.
Goldstein ST, Fiore AE: Toward the global elimination of hepatitis B virus transmission. J Pediatr 2001, 139:343–345.
Armstrong GL, Mast EE, Wojczynski M, Margolis HS: Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001, 108:1123–1128.
Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. Can J Gastroenterol 2000, 14:5B-20B.
Chongrisawat V, Poovorawan Y: Management of chronic hepatitis B and C virus infections. Indian J Pediatr 2002, 69:149–154. An excellent overview of the natural history, diagnostic techniques, and treatment options for children chronically infected with either HBV or HCV from the Virus Hepatitis Research Unit in Bangkok, Thailand, where these pediatric infections are common.
Sokal EM, Conjeevaram HS, Roberts EA, et al.: Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998, 114:988–995.
Bortolotti F, Jara P, Barbera C et al.: Long-term effect of alpha interferon in children with chronic hepatitis B. Gut 2000, 46:715–718.
Jara P, Bortolotti F: Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999, 29:163–170.
Barlow CF, Priebe CJ, Mulliken JB, et al.: Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1988, 132:527–530.
Sokal EM, Roberts EA, Mieli-Vergani G, et al.: A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000, 44:590–597.
Jonas MM, Kelley DA, Mizerski J, et al.: Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002, 346:1706–1713. This randomized, controlled multinational trial of 288 children with chronic HBV is designed well and should serve as a model for future antiviral trials in children with HBV.
Dikici B, Bosnak M, Bosnak V, et al.: Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatrics Int 2002, 44:517–521.
Shapira R, Mor E, Bar-Nathan N, et al.: Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. Transplantation 2001, 72:333–336.
Shapira R, Daudi N, Klein A, et al.: Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance. Transplantation 2002, 73:820–821.
Bhimma R, Coovadia HM, Kramvis A, et al.: Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002, 17:393–399.
Ohto H, Terazawa S, Sasaki N, et al.: Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994, 330:744–750.
Zanetti AR, Tanzi E, Romano L et al.: A prospective study of mother-to-infant transmission of hepatitis C virus. Interviology 1998, 41:208–212.
Thomas DL, Villano SA, Riester KA et al.: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998, 177:1480–1488.
Chang MH, Ni YM, Hwang LH et al.: Long term clinical and virologic outcome of primary hepatitis C virus infection in children: a prospective study. Pediatr Infect Dis J 1994, 13:769–773.
Vogt M, Lang T, Frosner G et al.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999, 341:866–870.
Zancan L, Strafella MS, Brugiolo A, et al. Chronic hepatitis C virus infection in childhood and early cirrhosis: Is it possible? J Pediatr Gastroenterol Nutr 2000, 30:350–351.
Mast EE, Alter MJ, Margolis HS: Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999, 17:1730–1733.
Kesson AM: Review article: Diagnosis and management of paediatric hepatitis C virus infection. J Paediatr Child Health 2002, 38:213–218. An excellent review of diagnostic techniques, epidemiology, and management considerations for HCV in the pediatric age group.
Jacobson KB, Murray K, Zellos A, Schwarz KB: An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002, 343:52–58. A review of the 366 treated and 105 untreated children with chronic hepatitis C reported in the English language. Includes a critique of the largely uncontrolled trials and makes recommendations for improving study design in the future.
Carithers RL, Emerson SS: Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997, 26(bdSuppl):83S-88S.
Davison S: Chronic hepatitis. In Diseases of the Liver and Biliary System in Children, edn 1. Edited by Kelly DA. Oxford: Blackwell Science; 1999:97–123.
Bunn S, Kelly D, Murray KF, et al.: Safety, efficacy and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic hepatitis C [abstract]. Hepatology 2000, 32:350A.
Woynarowski M, Socha J, Kuidowicz J, et al.: Interferon+ ribavirin vs interferon alone in treatment of children with chronic HCV infection [abstract]. J Hepatic 2001, 34(Suppl 1):139S.
Lackner H, Moser A, Deutsch J, et al.: Interferon-alfa and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000, 106:1–4.
Christensson B, Wiebe T, Akesson A, et al.: Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000, 30:585–586.
Wirth S, Lang T, Gehring S, Gerner P: Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002, 36:1280–1284.
Li CK, Chan PK, Ling SC, Ha SY: Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassemia major. Br J Maematol 2002, 117:755–758.
Strader DB: Understudied populations with hepatitis C. Hepatology 2002, 36:S226-S236.
Mathurin P, Mouquet C, Poynard T, et al.: Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999, 29:257–263.
Rostaing L, Modesto A, Baron E, et al.: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996, 74:512–516.
Resti M, Azzari C, Bortolotti F. Hepatitis C virus infection in children coinfected with HIV. Pediatr Drugs 2002, 4:571–580. An excellent review of the epidemiology, viral interactions, and treatment considerations of coinfected children. It also contains an up-todate review of treatment results in children infected with HCV alone.
Ruiz Moreno M, Jiminez J, Porres JC, et al.: A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990, 45:26–33.
Ruiz Moreno M, Rua MJ, Molina J, et al.: Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991, 13:1035–1039.
Utili R, Sagnelli E, Galanti B, et al.: Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2ainterferon: a controlled, randomized study. Am J Gastroenterol 1991, 86:327–330.
Sokal EM, Wirth S, Goyens P, et al.: Interferon alfa-2b therapy in children with chronic hepatitis B. Gut 1993, 34:S87-S90.
Barbera C, Bortolotti F, Crivellaro C, et al.: Recombinant interferon-alpha 2a hastens the rate of HbeAg clearance in children with chronic hepatitis B. Hepatology 1994, 20:287–290.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwarz, K.B. Pediatric issues in new therapies for hepatitis B and C. Curr Gastroenterol Rep 5, 233–239 (2003). https://doi.org/10.1007/s11894-003-0025-7
Issue Date:
DOI: https://doi.org/10.1007/s11894-003-0025-7